Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | KRAS | P01116 | 1/20 | 0.30 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.30 |
| ▸ | CTSA | P10619 | 1/20 | 0.30 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.30 |
| ▸ | OGG1 | O15527 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL932878 | 0.88 | APLNR (0.33) | APLNRMEN1HTTKMT2ASLC6A2 | |
| SCHEMBL933398 | 0.87 | APLNR (0.39) | APLNRSLC6A2SLC6A4IDO1TDO2 | |
| SCHEMBL6525291 | 0.83 | CYP2C19 (0.39) | MEN1KMT2ACA2 | |
| SCHEMBL29089769 | 0.78 | CTSA (0.46) | APLNRHTTIDO1TDO2CTSA | |
| SCHEMBL20854984 | 0.77 | MAPT (0.35) | APLNRIDO1CA2 | |
| SCHEMBL31257389 | 0.77 | MAPT (0.35) | APLNRIDO1CA2 | |
| SCHEMBL24010070 | 0.76 | APLNR (0.41) | APLNRSLC6A4IDO1TDO2KRAS | |
| SCHEMBL6160560 | 0.76 | APLNR (0.41) | APLNRSLC6A4IDO1TDO2KRAS | |
| SCHEMBL30161153 | 0.76 | APLNR (0.41) | APLNRSLC6A4IDO1TDO2KRAS | |
| SCHEMBL20854970 | 0.75 | AOC3 (0.35) | APLNRSLC6A2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2451793-B1 | BACE INHIBITORS | LILLY CO ELI (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2451793-B1 | BACE INHIBITORS | LILLY CO ELI (US) | 2016-11-02 | — | — | EP | disclosed |
| US-20120323001-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120323001-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-12-20 | — | — | US | disclosed |
| US-8278441-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278441-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| EP-2451793-A1 | BACE INHIBITORS | Eli Lilly and Company (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20110009395-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009395-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | US | disclosed |
| WO-2011005738-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120323001-A1 | BACE INHIBITORS | BACE1, BACE2, APP | APLNR 2742/4885MEN1 2551/4885HTT 1051/4885 |
| US-20110009395-A1 | BACE INHIBITORS | BACE1, BACE2, APP | APLNR 2742/4885MEN1 2551/4885HTT 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.